NDATRANSDERMALSYSTEM
Approved
Mar 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
XELSTRYM (dextroamphetamine) by Noven Pharmaceuticals is clinical pharmacology amphetamines are noncatecholamine, sympathomimetic amines with cns stimulant activity. First approved in 2022.
Drug data last refreshed 23m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XELSTRYM is a transdermal dextroamphetamine system indicated for attention-deficit/hyperactivity disorder (ADHD) treatment. It is a CNS stimulant that elevates systolic and diastolic blood pressure and provides weak bronchodilator activity. The transdermal formulation offers an alternative delivery route to traditional oral amphetamine products, with a half-life of approximately 11.75 hours.
$0.051BPart D
Peak15.5 years to LOEProduct is at peak lifecycle with modest Part D uptake (103 claims in 2023), indicating early commercialization phase with potential for modest team expansion in sales and marketing.
Mechanism of Action
CLINICAL PHARMACOLOGY Amphetamines are noncatecholamine, sympathomimetic amines with CNS stimulant activity. Peripheral actions include elevations of systolic and diastolic blood pressures and weak bronchodilator and respiratory stimulant action. There is neither specific evidence that clearly…
Pharmacologic Class:
Central Nervous System Stimulant
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine
Started Oct 2019
430,000 enrolled
Attention Deficit Disorder With Hyperactivity
Worked on XELSTRYM at Noven Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.